Penpulimab-kcqx — CPB 1080 | AETNA Coverage Update

Aetna modified CPB 1080 for penpulimab-kcqx, effective December 4, 2025. Here's what billing teams need to do.

Aetna, a CVS Health company, updated its penpulimab-kcqx coverage policy under CPB 1080 on December 4, 2025. This policy governs reimbursement for penpulimab-kcqx in commercial plan members with non-keratinizing nasopharyngeal carcinoma (NPC). Billing teams administering this drug need to verify prior authorization, site-of-care requirements, and combination chemotherapy coding — specifically CPT codes 96413, 96414, and 96415, plus HCPCS codes for cisplatin (J9060), carboplatin (J9045), and gemcitabine (J9201, J9196, J9198) — before submitting claims.

Quick-Reference Table

Aetna Penpulimab-kcqx Coverage Criteria and Medical Necessity Requirements 2025

The Aetna penpulimab-kcqx coverage policy covers two distinct clinical scenarios. Both require prior authorization. Neither will pay without it.

First-line recurrent or metastatic NPC: Aetna considers penpulimab-kcqx medically necessary when used as first-line treatment of recurrent or metastatic non-keratinizing NPC. The drug must be given in combination with either cisplatin (J9060) or carboplatin (J9045) and gemcitabine (J9201, J9196, or J9198) for six cycles. After those six cycles, penpulimab-kcqx continues as a single agent. This is a strict sequence — the combination-then-monotherapy structure is part of the medical necessity criteria, not just clinical practice.

Second-line or later metastatic NPC: Aetna also considers penpulimab-kcqx medically necessary as a single agent for metastatic disease. The member must have had progression on or after platinum-based chemotherapy and at least one other prior line of therapy. That's two prior treatment lines minimum before single-agent penpulimab-kcqx qualifies.

For prior authorization, call Aetna at (866) 752-7021 or fax (888) 267-3277. Statement of Medical Necessity forms are available through Aetna's Specialty Pharmacy Precertification portal.

Site of care matters here. Aetna's Site of Care Utilization Management Policy applies to penpulimab-kcqx. That means the infusion setting needs to be approved, not just the drug. If your patient gets this drug in an office versus an outpatient infusion center, confirm which site Aetna authorized before you bill 96413 or 96415.

Continuation of therapy is also covered — up to 24 months total — as long as reauthorization is requested and there is no evidence of unacceptable toxicity or disease progression. That 24-month cap is the ceiling. Plan your reauthorization cadence accordingly.

Aetna Penpulimab-kcqx Exclusions and Non-Covered Indications

This section is short, but the exclusion is absolute. Aetna will not cover penpulimab-kcqx for any member who has experienced disease progression while on PD-1 or PD-L1 inhibitor therapy.

Read that carefully. Penpulimab-kcqx is itself a PD-1 inhibitor. The intent of this exclusion is to block use in patients who already failed a PD-1 or PD-L1 checkpoint inhibitor — including prior pembrolizumab, nivolumab, or similar agents. If your patient progressed on one of those drugs and someone is requesting penpulimab-kcqx next, Aetna won't pay. Full stop.

This is one of those exclusions that generates claim denial if it isn't caught at the authorization stage. Confirm the patient's prior immunotherapy history before submitting the precertification. Document that the patient has not had disease progression on a PD-1 or PD-L1 inhibitor. If the prior treatment history is unclear, flag it for your oncology clinical team before you submit.

All indications not specifically listed — meaning anything outside non-keratinizing NPC in the approved scenarios — are considered experimental, investigational, or unproven by Aetna. There is no off-label pathway here under this coverage policy.

Coverage Indications at a Glance

Aetna Penpulimab-kcqx Billing Guidelines and Action Items 2025

These are the steps your billing and authorization teams need to take now. The effective date is December 4, 2025. If you're seeing these cases in your queue, the policy is already active.

1. Confirm prior auth is in place before every infusion.
Penpulimab-kcqx requires precertification on all Aetna commercial plans. No authorization, no coverage. Call (866) 752-7021 or fax (888) 267-3277. Do not assume a standing auth covers new cycles.

2. Verify site-of-care authorization separately.
Aetna's Site of Care UM Policy applies to this drug. The location of infusion must be approved. If your practice recently changed infusion settings — or if a patient moved to a different facility — reconfirm the site-of-care authorization. A drug auth and a site auth are two different things. Missing the site auth will generate a denial even when the drug is authorized.

3. Code combination regimens with the correct HCPCS for each drug.
For first-line combination therapy, you'll bill penpulimab-kcqx alongside the platinum agent and gemcitabine. Use J9060 for cisplatin (per 10 mg) or J9045 for carboplatin (per 50 mg). For gemcitabine, use J9201 (generic, 200 mg), J9196 (Accord brand, 200 mg), or J9198 (Infugem brand, 100 mg) based on what was actually dispensed. Don't swap gemcitabine codes arbitrarily — Aetna's policy lists all three, but the claim should match the actual product.

4. Document the treatment line clearly in the medical record before submitting for second-line authorization.
For single-agent second-line requests, Aetna requires progression on platinum-based chemotherapy and at least one other prior line. Your authorization request needs to document both. "Platinum-refractory" alone isn't enough. Pull the full prior treatment history and include it in the SMN submission.

5. Document PD-1/PD-L1 prior treatment status at intake.
Before you submit any prior auth for penpulimab-kcqx, check whether the patient has been on a PD-1 or PD-L1 inhibitor and whether they progressed on it. If they did, this drug is excluded under CPB 1080 — full stop. Catching this before submission saves your team the turnaround time on a guaranteed denial.

6. Track the 24-month therapy clock and schedule reauths in advance.
Continuation of therapy is covered up to 24 months total. Build that end date into your authorization tracking system when you get initial approval. Set a reauthorization reminder at least 30 days before expiration. Aetna requires no evidence of disease progression or unacceptable toxicity for continued coverage — make sure those clinical notes are current at reauth time.

7. Check the ICD-10 code specificity on every claim.
Aetna's policy is specific to non-keratinizing NPC. Use the most specific C11.x code available. C11.9 (unspecified) is acceptable when the sub-site isn't documented, but if the chart specifies the sub-site, code it. Use the full range C11.0 through C11.9 as appropriate to the documented diagnosis.

If you're unsure how this policy applies to your patient mix or authorization workflow, talk to your billing consultant or compliance officer before submitting claims under the December 4, 2025 effective date.

CPT, HCPCS, and ICD-10 Codes for Penpulimab-kcqx Under CPB 1080

Covered CPT Codes (When Medical Necessity Criteria Are Met)

Covered HCPCS Codes (Combination and Supportive Agents)

Note on J9263: Oxaliplatin appears in the code list but is not part of the approved first-line combination regimen described in the coverage criteria. The approved platinum agents are cisplatin (J9060) and carboplatin (J9045). If your team is considering oxaliplatin as a substitute, do not assume it qualifies — the policy language is specific to cisplatin and carboplatin. Confirm with Aetna before using J9263 in a penpulimab-kcqx combination claim.

ICD-10-CM Diagnosis Codes

The descriptions above reflect exactly what CPB 1080 lists for each C11.x code. Aetna's policy does not break out sub-site descriptions by code. If you need anatomic sub-site specificity for coding purposes — superior wall, posterior wall, lateral wall, and so on — consult the ICD-10-CM tabular list directly. The clinical restriction in this policy is histologic type (non-keratinizing), not anatomic location. Use the most specific code supported by the documentation.